Literature DB >> 8961061

Antimicrobial practice. Development of guidelines for gentamicin dosing.

A H Thomson1, N Duncan, B Silverstein, S Alcock, D Jodrell.   

Abstract

The performance of dosage guidelines for starting gentamicin therapy was evaluated prospectively in 50 patients with suspected or proven Gram-negative septicaemia and the results were compared with results from similar group of 50 patients for whom the guidelines were not followed. Peak concentrations were significantly higher when the guidelines were followed (7.2 (+/- 1.9) mg/L vs 5.7 (+/- 1.8) mg/L) but there was no difference in trough concentrations. Fifty-eight per cent of patients had both peak and trough concentrations within the target range (peak > 5 mg/L, trough < 2 mg/L) when doses were decided empirically; this increased to 96% when the guidelines were followed. However, use of the guidelines achieved peaks of > 7 mg/L in only 56% of patients. A revised protocol with higher doses given less frequently was therefore developed and a prospective assessment of its performance indicated that satisfactory concentrations were obtained in 96% of patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8961061     DOI: 10.1093/jac/38.5.885

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

1.  Doripenem, gentamicin, and colistin, alone and in combinations, against gentamicin-susceptible, KPC-producing Klebsiella pneumoniae strains with various ompK36 genotypes.

Authors:  Cornelius J Clancy; Binghua Hao; Ryan K Shields; Liang Chen; David S Perlin; Barry N Kreiswirth; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

2.  Pharmacokinetic-pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillin-resistant Staphylococcus aureus.

Authors:  Reiko Sato; Yusuke Tanigawara; Mitsuo Kaku; Naoki Aikawa; Kihachiro Shimizu
Journal:  Antimicrob Agents Chemother       Date:  2006-11       Impact factor: 5.191

3.  Aminoglycoside use in renal failure.

Authors:  S Nayak-Rao
Journal:  Indian J Nephrol       Date:  2010-07

4.  Population pharmacokinetics of gentamicin in patients with cancer.

Authors:  M C Rosario; A H Thomson; D I Jodrell; C A Sharp; H L Elliott
Journal:  Br J Clin Pharmacol       Date:  1998-09       Impact factor: 4.335

5.  Predictive performance of gentamicin dosing nomograms.

Authors:  Jieon Lee; Seonghae Yoon; Donghoon Shin; HyeKyung Han; Hyungmi An; Jongtae Lee; Kyoung Soo Lim; Kyung-Sang Yu; Howard Lee
Journal:  Drug Des Devel Ther       Date:  2014-08-16       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.